Protective Cancer Vaccine Using Genetically Modified Hematopoietic Stem Cells

Area of Science:

• Immunology
• Cancer Research
• Stem Cell Biology

Background:

• Hematopoietic stem cells (HSCs) generate diverse blood cell lineages.
• Reprogramming HSCs into tumor antigen-specific cytotoxic T lymphocytes (CTLs) offers potential for cancer immunotherapy.
• Optimal methods for generating HSC-derived CTLs remain under investigation.

Purpose of the Study:

• To investigate a combined strategy of HSC genetic modification and in vivo T cell development for generating tumor-specific CTLs.
• To assess the anti-tumor efficacy of HSC-derived CTLs in a murine melanoma model.

Main Methods:

• Murine HSCs were genetically modified to express an ovalbumin (OVA)-specific T cell receptor.
• Adoptive transfer of modified HSCs into recipient mice followed by in vivo T cell development using an agonist α-Notch 2 antibody and cytokines (rFlt3L, rIL-7).
• Challenging mice with B16-OVA melanoma cells and assessing anti-tumor activity of HSC-derived T cells.

Main Results:

• In vivo development of OVA-specific CTLs from genetically modified HSCs was achieved.
• HSC-derived CTLs exhibited a robust response to OVA antigen stimulation ex vivo.
• Mice treated with modified HSCs and in vivo priming demonstrated suppressed tumor growth, indicating established anti-tumor immunity.

Conclusions:

• A combined approach of genetic modification of HSCs and in vivo T cell development effectively generates tumor antigen-specific CTLs.
• This strategy establishes anti-tumor immunity and suppresses tumor growth in a preclinical model.
• The findings present a novel strategy for developing cancer vaccines using genetically modified HSCs.